论文部分内容阅读
目的:探讨非小细胞肺癌(NSCLC)患者血清SiSo细胞表达的受体结合肿瘤抗原(RCAS1)水平及其临床意义。方法:采用酶联免疫吸附法(ELISA)定量检测102例NSCLC患者和40例良性肺部疾病患者血清RCAS1水平,并以35名正常人血清作为对照,比较不同分期、有无转移及术后1年复发与否的患者之间是否存在差异。结果:NSCLC组血清RCAS1水平〔(48.6±18.5)U/mL〕显著高于健康对照组〔(13.5±11.8)μg/mL;t=7.56,P=0.000〕和良性肺部疾病组〔(18.3±14.8)μg/mL;t=3.73,P=0.001〕。Ⅲ/Ⅳ期患者血清RCAS1水平〔(60.8±16.3)U/mL〕显著高于Ⅰ/Ⅱ期患者〔(34.6±15.3)U/mL;t=3.56,P=0.000〕。有转移患者和术后1年内复发患者血清RCAS1水平〔(58.3±16.9)、(59.6±14.9)U/mL〕分别高于无转移患者和无复发患者〔(35.6±13.2)、(33.8±13.6)U/mL〕,P值分别为0.002、0.001。结论:NSCLC患者血清RCAS1表达水平有可能作为肿瘤转移和术后复发的预测指标。
Objective: To investigate the level of receptor-bound tumor antigen (RCAS1) expressed in serum SiSo cells in patients with non-small cell lung cancer (NSCLC) and its clinical significance. Methods: The levels of serum RCAS1 in 102 patients with NSCLC and 40 patients with benign lung disease were detected by enzyme-linked immunosorbent assay (ELISA). 35 serum samples of normal people were used as control to compare the different stages, metastasis and postoperative 1 Year recurrence or not whether there is a difference between patients. Results: Serum RCAS1 levels (48.6 ± 18.5) U / mL in NSCLC group were significantly higher than those in healthy control group (13.5 ± 11.8 μg / mL; t = 7.56, P = 0.000) ± 14.8) μg / mL; t = 3.73, P = 0.001]. Serum levels of RCAS1 in patients with stage III / IV 〔(60.8 ± 16.3) U / mL〕 were significantly higher than those in patients with stage Ⅰ / Ⅱ 〔(34.6 ± 15.3) U / mL; t = 3.56, P = 0.000〕. The levels of serum RCAS1 in patients with metastasis and recurrence within 1 year after surgery were (58.3 ± 16.9) and (59.6 ± 14.9) U / mL, respectively, higher than those without metastasis and with no recurrence 〔(35.6 ± 13.2), (33.8 ± 13.6 ) U / mL], P values were 0.002,0.001. Conclusion: The expression of serum RCAS1 in patients with NSCLC may be used as a predictor of tumor metastasis and recurrence.